doxazosin has been researched along with Pain in 7 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
Excerpt | Relevance | Reference |
---|---|---|
"The efficacy of doxazosin monotherapy in chronic non-bacterial prostatitis was investigated in terms of urinary symptom, pain and quality of life assessment versus placebo." | 9.10 | Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo. ( Burgut, R; Evliyaoğlu, Y, 2002) |
" However, the incidence of nocturnal enuresis, urgency attacks, and daytime incontinence were significantly reduced compared with baseline in the tizanidine group (P=." | 5.16 | Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial. ( Dawaba, M; El-Assmy, MM; El-Hefnawy, AS; Hafez, AT; Helmy, T; Sarhan, O, 2012) |
"The efficacy of doxazosin monotherapy in chronic non-bacterial prostatitis was investigated in terms of urinary symptom, pain and quality of life assessment versus placebo." | 5.10 | Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo. ( Burgut, R; Evliyaoğlu, Y, 2002) |
" The former was treated by applying the CRS-2280E extraorgan short-wave capacitance field hyperthermia system to the prostate once an hour every other day for 7 times, combined with anal administration of 1 Qianliean suppository and oral doxazosin 4 mg before bedtime every night for 2 weeks, while the latter underwent simple local hyperthermia." | 2.73 | [Medication combined with local hyperthermia: a desirable therapy for chronic prostatitis pain symptoms]. ( Sun, FL; Zang, T; Zhang, Y, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Monastirli, A | 1 |
Georgiou, S | 1 |
Chroni, E | 1 |
Pasmatzi, E | 1 |
Papathanasopoulos, P | 1 |
Tsambaos, D | 1 |
Sen, H | 1 |
Erturhan, S | 1 |
Sadioglu, E | 1 |
Bayrak, O | 1 |
Seckiner, İ | 1 |
Zhang, Y | 1 |
Sun, FL | 1 |
Zang, T | 1 |
Resorlu, B | 1 |
Bozkurt, OF | 1 |
Senocak, C | 1 |
Unsal, A | 1 |
El-Hefnawy, AS | 1 |
Helmy, T | 1 |
El-Assmy, MM | 1 |
Sarhan, O | 1 |
Hafez, AT | 1 |
Dawaba, M | 1 |
Evliyaoğlu, Y | 1 |
Burgut, R | 1 |
Batchelor, RJ | 1 |
Lyon, CC | 1 |
Highet, AS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin[NCT00971620] | Phase 2 | 18 participants (Actual) | Interventional | 2008-11-17 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale is 0-10. 10 denotes worse pain than 0. (NCT00971620)
Timeframe: Between week 12 and 24
Intervention | Score (Median) |
---|---|
BTX-A | 4.10 |
Placebo/Saline | -0.30 |
Change in worst lesional pain in the past week based on Brief Pain Inventory (BPI) from Week 0 to Week 4 in treated patients versus controls. The BPI uses an arbitrary units on a 0-10 scale. For the purposes of the statistical calculation, a difference of 1 standard deviation between groups at baseline vs. week 4 was considered significant. Any BPI value above zero (no pain) is abnormal. The mean change indicates mean change in pain score. (NCT00971620)
Timeframe: Between week 0 and week 4
Intervention | units on a scale (Mean) |
---|---|
BTX-A | -2.50 |
Placebo/Saline | -1.26 |
The DLQI is a 10-question quality of life survey which has been extensively validated and frequently used in dermatologic disorders such as atopic dermatitis, acne, and psoriasis. Score is 0-30 based on 10 questions. The higher the score, the more quality of life is impaired. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | Units on a scale (Median) |
---|---|
BTX-A | -4.00 |
Placebo/Saline | 0.00 |
AchE staining was scored as 0 (none), 1 (rare), 2 (scattered), or 3 (focal or greater). (NCT00971620)
Timeframe: Week 0 vs. week 12
Intervention | Score (Median) |
---|---|
BTX-A | 1.00 |
Placebo/Saline | 0.00 |
c-fos, a marker of neuronal activation after pain stimulation, was scored as 0 (none), 1 (scattered), 2 (<66% of tumor cells), or 3 (≥66% of tumor cells). (NCT00971620)
Timeframe: Week 0 vs. week 12
Intervention | Score (Median) |
---|---|
BTX-A | -1.00 |
Placebo/Saline | 0.00 |
Change in average pain was assessed by the Brief Pain Inventory (BPI). The BPI is a validated pain assessment tool that assesses severity of pain, location of pain, impact of pain on daily functions, pain medications, and amount of pain relief in the past 24 hours or past week (e.g. scale of 0-10 (worst pain)). (NCT00971620)
Timeframe: Between weeks 0 and week 4
Intervention | Score (Median) |
---|---|
BTX-A | 0.00 |
Placebo/Saline | 0.00 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00971620)
Timeframe: 37 months
Intervention | participants (Number) |
---|---|
BTX-A | 4 |
Placebo/Saline | 5 |
"The DLQI is a 10-question quality of life survey which has been extensively validated and frequently used in dermatologic disorders such as atopic dermatitis, acne, and psoriasis. Participants response to the question Over the last week, how itchy, sore, painful or stinging has your skin been? was assessed by the Dermatology Life Quality Index. This outcome refers to a single specific question on the DLQI, so the range for this outcome is 0-3. Lower values in the DLQI indicate less impairment (or greater improvement) in life quality from the skin disease." (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | Units on a scale (Median) |
---|---|
BTX-A | -1.00 |
Placebo/Saline | 0.00 |
The VAS is a commonly used validated tool for assessment of pain. For this measure, a 10-cm VAS was used to assess current patient pain/discomfort before application of ice to study lesions at week 0 and week 4. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Range is 0-10; 0 is no pain and 10 is worst possible pain. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | Score (Median) |
---|---|
BTX-A | 0.00 |
Placebo/Saline | 0.40 |
Pain severity was assessed by the Brief Pain Inventory (BPI). The BPI is a validated pain assessment tool that assesses severity of pain, location of pain, impact of pain on daily functions, pain medications, and amount of pain relief in the past 24 hours or past week (e.g. scale of 0-10 (worst pain)). This outcome was based on a single 0-10 question on the BPI. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | Score (Median) |
---|---|
BTX-A | -2.25 |
Placebo/Saline | -0.75 |
Average pain was determined from a 0-10 scale question on the Brief Pain Inventory (BPI). 10 denotes worse pain. (NCT00971620)
Timeframe: Week 0 score vs. week 4 score
Intervention | percentage of patients (Number) | ||||
---|---|---|---|---|---|
>50% pain reduction | ≤50% pain reduction | No change in pain | Increased pain | Missing | |
BTX-A | 44 | 0 | 22 | 22 | 11 |
Placebo/Saline | 22 | 11 | 33 | 22 | 11 |
The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale is 0-10. 10 = worse pain. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | percentage of patients (Number) | ||||
---|---|---|---|---|---|
>50% pain reduction | ≤50% pain reduction | No change in pain | Increased pain | Missing | |
BTX-A | 33 | 44 | 0 | 22 | 0 |
Placebo/Saline | 33 | 44 | 0 | 22 | 0 |
The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale of 0-10. 10 = worse pain. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | percentage of patients (Number) | ||||
---|---|---|---|---|---|
>50% pain reduction | ≤50% pain reduction | No change in pain | Increased pain | Missing | |
BTX-A | 22 | 33 | 0 | 11 | 33 |
Placebo/Saline | 11 | 0 | 11 | 55 | 22 |
4 trials available for doxazosin and Pain
Article | Year |
---|---|
A comparison of efficacy of doxazosin 4 and 8 mg in medical expulsive therapy of distal ureteral stones: a prospective randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Analgesics; Diclofenac; Dose-Response Relationship, | 2017 |
[Medication combined with local hyperthermia: a desirable therapy for chronic prostatitis pain symptoms].
Topics: Administration, Oral; Adolescent; Adrenergic alpha-Antagonists; Adult; Chronic Disease; Combined Mod | 2008 |
Doxazosin versus tizanidine for treatment of dysfunctional voiding in children: a prospective randomized open-labeled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Anorexia; Child; Chil | 2012 |
Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo.
Topics: Adrenergic alpha-Antagonists; Adult; Doxazosin; Humans; Male; Middle Aged; Pain; Pain Measurement; P | 2002 |
3 other studies available for doxazosin and Pain
Article | Year |
---|---|
Rapid and complete resolution of severe pain in multiple cutaneous leiomyomas by oral doxazosin.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Female; Humans; Leiomyoma; Pain; Skin Neop | 2014 |
Effectiveness of doxazosin in the management of lower ureteral stones in male and female patients.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; Anti-Inflammatory Agents, Non-Steroidal; | 2011 |
Successful treatment of pain in two patients with cutaneous leiomyomata with the oral alpha-1 adrenoceptor antagonist, doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Doxazosin; Female; Humans; Leiomyomatosis; Middle Aged; Pain; S | 2004 |